Vellucci S V, Webster R A
Eur J Pharmacol. 1984 Jan 27;97(3-4):289-93. doi: 10.1016/0014-2999(84)90462-x.
The effect of the benzodiazepine antagonist Ro15-1788 has been tested against caffeine (200-300 mg/kg i.p.) induced convulsions in mice. It offered protection in lower doses (10 mg/kg i.p.) than had been effective previously against other convulsants such as bicuculline and leptazol. In contrast, diazepam was much less active against caffeine than against the other convulsants and offered no significant protection in doses up to 1 mg/kg i.p. If Ro15-1788 only acts on benzodiazepine receptors then one explanation for the increased activity of Ro15-1788 compared with diazepam against caffeine is that caffeine exerts its convulsant action through a direct effect on benzodiazepine receptors but is more potent at displacing diazepam than Ro15-1788 or alternatively it acts on a sub-class of benzodiazepine receptors that bind Ro15-1788 more effectively than diazepam.
已针对咖啡因(腹腔注射200 - 300毫克/千克)诱导的小鼠惊厥测试了苯二氮䓬拮抗剂Ro15 - 1788的效果。与之前对抗荷包牡丹碱和戊四氮等其他惊厥剂有效的剂量相比,它在较低剂量(腹腔注射10毫克/千克)时就能提供保护。相比之下,地西泮对咖啡因的活性比对其他惊厥剂低得多,在腹腔注射高达1毫克/千克剂量时未提供显著保护。如果Ro15 - 1788仅作用于苯二氮䓬受体,那么与地西泮相比Ro15 - 1788对咖啡因活性增加的一种解释是,咖啡因通过对苯二氮䓬受体的直接作用发挥其惊厥作用,但在取代地西泮方面比Ro15 - 1788更有效,或者它作用于一类比地西泮更有效地结合Ro15 - 1788的苯二氮䓬受体亚类。